Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13277460 | 1.00 | NAMPT (0.55) | NAMPTGAAALDH1A1 | |
| SCHEMBL13276891 | 1.00 | NAMPT (0.55) | NAMPTGAAALDH1A1 | |
| SCHEMBL13045640 | 1.00 | NAMPT (0.55) | NAMPTGAAALDH1A1 | |
| SCHEMBL13277282 | 0.99 | NAMPT (0.54) | NAMPTGAA | |
| SCHEMBL13277628 | 0.99 | NAMPT (0.54) | NAMPTGAA | |
| SCHEMBL13277281 | 0.99 | NAMPT (0.54) | NAMPTGAA | |
| SCHEMBL13449941 | 0.99 | NAMPT (0.54) | NAMPTGAA | |
| SCHEMBL13449949 | 0.99 | NAMPT (0.54) | NAMPTGAA | |
| SCHEMBL13557043 | 0.94 | NAMPT (0.47) | NAMPT | |
| SCHEMBL13277086 | 0.87 | NAMPT (0.55) | NAMPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | TOPO TARGET A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | TOPO TARGET A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2011006988-A1 | METHOD FOR PREDICTING THE UTILITY OF ADMINISTERING NICOTINIC ACID OR A PRECURSOR OR PRODRUG THEREOF TO REDUCE THE SEVERITY OF SIDE-EFFECTS OF CANCER TREATMENT WITH NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS | TOPOTARGET A/S (DK) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270900-A1 | NOVEL METHOD OF TREATMENT | NAPRT, NAMPT, NNT | NAMPT 2/4885GAA 1028/4885ALDH1A1 722/4885 |
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | NAMPT 1/4885GAA 1756/4885ALDH1A1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.